Zlotta A - Search Results

1

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Neuzillet Y, et al. Among authors: zlotta a. Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461579 French. No abstract available.

2

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Shariat SF, et al. Mod Pathol. 2007 Apr;20(4):445-59. doi: 10.1038/modpathol.3800757. Epub 2007 Mar 2. Mod Pathol. 2007. PMID: 17384651 Free article.

3

Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.

Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Gupta A, et al. Among authors: zlotta ar. Clin Cancer Res. 2008 Nov 15;14(22):7385-90. doi: 10.1158/1078-0432.CCR-07-5110. Clin Cancer Res. 2008. PMID: 19010854

4

Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology.

Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R. Van der Kwast TH, et al. Among authors: zlotta ar. Anal Quant Cytol Histol. 2008 Dec;30(6):309-15. Anal Quant Cytol Histol. 2008. PMID: 19160695

5

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. van Rhijn BW, et al. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Eur Urol. 2009. PMID: 19576682 Review.

6

The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma.

Ordon M, Boerner S, Zlotta AR, Jewett MA, Fleshner N. Ordon M, et al. Among authors: zlotta ar. BJU Int. 2009 Dec;104(11):1641-5. doi: 10.1111/j.1464-410X.2009.08650.x. Epub 2009 Jul 2. BJU Int. 2009. PMID: 19583723

7

The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boevé ER, Jöbsis AC, van der Kwast TH. van Rhijn BW, et al. Eur Urol. 2010 Jun;57(6):1052-7. doi: 10.1016/j.eururo.2009.09.022. Epub 2009 Sep 11. Eur Urol. 2010. PMID: 19765886

8

Impact of positive surgical margins after radical prostatectomy differs by disease risk group.

Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, Nesbitt M, Lockwood G, Trachtenberg J. Alkhateeb S, et al. Among authors: zlotta a. J Urol. 2010 Jan;183(1):145-50. doi: 10.1016/j.juro.2009.08.132. J Urol. 2010. PMID: 19913824

9

Pathological stage review is indicated in primary pT1 bladder cancer.

van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR. van Rhijn BW, et al. Among authors: zlotta ar. BJU Int. 2010 Jul;106(2):206-11. doi: 10.1111/j.1464-410X.2009.09100.x. Epub 2009 Dec 9. BJU Int. 2010. PMID: 20002439

10

The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Zlotta AR, Fleshner NE, Jewett MA. Zlotta AR, et al. Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S199-205. doi: 10.5489/cuaj.1196. Can Urol Assoc J. 2009. PMID: 20019985 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page